SWEEP
Sweep, the leading carbon management and reduction platform, today announced it has expanded its leadership team with the recruitment of former French Minister of Agriculture and Food Julien Denormandie as Chief Impact Officer. He officially joined on September 5.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220906005500/en/
Julien Denormandie (Photo: Cheick Saidou)
Julien Denormandie said: "I am thrilled to start this new chapter at Sweep. Recent years, and especially the last few months, have shown us that the fight against climate change is the challenge of the century. It also reminded us of the need to develop concrete, applicable solutions that generate results. Sweep perfectly aligns with this virtuous approach by helping companies to measure and reduce their carbon emissions. In my new role as Chief Impact Officer, I want to use my experience, coupled with the market-leading tools that Sweep has created, to support businesses in their climate journey and become agents of positive change in the low carbon economy.”
Julien Denormandie will work alongside Sweep’s four co-founders to pursue the efforts that have already established the French start-up as one of the fastest-growing climate tech firms and a trusted partner to organisations around the world.
The challenges of reducing carbon emissions are both related to the massive amount of data that needs to be collected and evaluated, and to network issues due to the vast number of stakeholders involved. Julien will be in charge of strengthening Sweep’s network approach to carbon management to help maximise the impact of their climate action. His remit will also include growing the business, both in France and internationally, and further establishing Sweep’s position as a leading partner to organisations committed to a low-carbon future.
Rachel Delacour, CEO and co-founder of Sweep said, "The challenge of reversing the spiral of climate change is massive. Our ambition is to help organisations transition to a model that will thrive in a low carbon economy. Julien Denormandie's arrival is at the heart of this ambition. He joins at a time when Sweep is entering a new stage of its growth and I am delighted that we will continue to develop our platform and offer together. He has a unique ability to solve complex, multidimensional problems, which is the very essence of the challenges facing organisations when reducing carbon emissions today. This is in Sweep's DNA and Julien's too!”
Minister of Agriculture and Food from July 2020 to May 2022 in Jean Castex's government, Julien Denormandie was previously Deputy to the Minister of Territorial Cohesion in the government of Edouard Philippe between June 2017 and October 2018 and then Minister in charge of Cities and Housing until July 2020. He was successively advisor to the Minister in charge of Foreign Trade, Nicole Bricq, to the Minister of Economy and Finance, Pierre Moscovici before becoming Deputy Chief of Staff of the Minister of Economy, under Emmanuel Macron between 2012 and 2016. Ingénieur des ponts, des eaux et des forêts, he began his career on secondment to the Department of External Relations of the Ministry of the Economy before holding various positions at the French Embassy in Cairo and at the Treasury Department.
About Sweep
Sweep helps businesses track and act on their carbon so they can become forever companies.
The data-driven platform makes it easy to understand, manage and reduce your carbon footprint. Powerful collaboration features and user-focused design empower your staff and your entire value chain to grow a cleaner business. The platform also has an integrated marketplace, letting you contribute to exciting carbon reduction and removal projects around the world. And with all your data in one place, its analytics offer deep insights into your progress and automatic reporting to your stakeholders.
Sweep is B Corp certified and a member of the World Bank’s Carbon Pricing Leadership Coalition and The International Emissions Trading Association. Visit sweep.net to learn more.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220906005500/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TreeFrog Therapeutics Announces Changes to Executive Committee With the Arrival of Mark Rothera as Chief Executive Officer & Board Member to Spearhead Next Phase of Growth16.12.2025 09:05:00 CET | Press release
TreeFrog Therapeutics, a French biotech focused on bringing regenerative medicine to millions through their proprietary cell technology, C-Stem™ is delighted to announce the appointment of skilled biotech leader, Mark Rothera, as Chief Executive Officer and Board member. He succeeds Frédéric Desdouits, who is stepping down after five years in the role. In the new leadership configuration, co-founders Kévin Alessandri and Maxime Feyeux will transition from daily operations to focus on their roles on the Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251215145193/en/ Mark Rothera, CEO TreeFrog Therapeutics Elsy Boglioli, Chair of the Board of TreeFrog Therapeutics, commented “On behalf of the Board, we are delighted to welcome Mark to TreeFrog. His 30+ years of biopharma leadership, including most recently, three biotech CEO roles in gene therapy and biologics, will be invaluable as we advance our Parkinson’s and liver
RoslinCT and Ayrmid Ltd. Announce Expansion of Strategic Partnership to Manufacture Omisirge® (omidubicel-onlv) for Second FDA-Approved Indication in Severe Aplastic Anemia (SAA)16.12.2025 09:00:00 CET | Press release
RoslinCT is performing technology transfer and will support commercial manufacture of Omisirge® for an additional indication following successful clinical trialsOmisirge® now FDA-approved for an expanded patient population in hematologyRoslinCT continues to support and advance multiple cell therapy projects at its Hopkinton, MA facility Ayrmid Ltd., the parent company of Gamida Cell Inc., a pioneering cell therapy company transforming cells into powerful therapeutics, and RoslinCT, a global leader in cell and gene therapy contract development and manufacturing, today announced the expansion of their strategic partnership to include the execution of a commercial supply agreement to support production of Omisirge® (omidubicel-onlv). Following positive clinical trial results, Omisirge® has received FDA approval for a second indication, broadening its use in the treatment of hematology patients. Under the commercial supply agreement, RoslinCT will complete technology transfer and support c
Echoworx Secures FSQS-Netherlands Certification, Strengthening Trust in Financial Data Protection16.12.2025 07:00:00 CET | Press release
Leading encryption provider deepens commitment to European financial sector with rigorous new supplier qualification, building on existing UK & Ireland certification. Echoworx, a global leader in email and data encryption, proudly announces it has achieved Financial Services Qualification System (FSQS) registered supplier status for the Netherlands. This certification powerfully demonstrates Echoworx’s commitment to the highest standards of security and compliance. This achievement expands on the company’s existing FSQS certification for the UK and Ireland, secured in 2020. By successfully completing the rigorous qualification for the Netherlands, Echoworx reinforces its alignment with the stringent demands of the European financial market. The FSQS system, managed by Hellios, provides a single, reliable standard for vetting third-party suppliers, streamlining procurement for major banks and financial institutions. Think of FSQS as a high-security passport for technology partners. It p
Nippon Electric Glass to Start World’s First Mass Production of Low-Carbon Pharmaceutical Glass Tubing Using an All-Electric Furnace16.12.2025 03:00:00 CET | Press release
Nippon Electric Glass Co., Ltd. (NEG)(TOKYO:5214), a global leader in specialty glass headquartered in Otsu, Japan, announced it will begin the world’s first mass production of pharmaceutical-grade glass tubing using an all-electric melting furnace. Commercial production is scheduled to start in December 2025 at its subsidiary in Selangor, Malaysia. This breakthrough introduces a new manufacturing model for pharmaceutical packaging. By combining NEG’s proprietary all-electric melting technology with renewable energy, CO2 emissions from glass tubing production can be reduced by up to 90%*1 compared with conventional fossil-fuel combustion furnaces. This positions NEG as a major supplier capable of delivering both high-performance borosilicate glass and a significantly lower carbon footprint, directly addressing global sustainability demands from pharmaceutical companies and regulators. NEG is a leading global supplier of arsenic-free, environmentally friendly borosilicate glass tubing f
Esco Aster Signs Exosome Clinical cGMP Manufacturing Contract With Shine-On Biomedical For A Novel First-In-Class HLA-G Targeting Exosome Drug Delivery Platform16.12.2025 02:00:00 CET | Press release
Esco Aster, a vertically integrated cell and derivatives CRDMO based at JTC LaunchPad Singapore, announced CMC manufacturing support for Shine-On Biomedical’s HLA-G targeted exosome program. Shine-On Biomedical sponsored Esco Aster in 2023 for cGMP services, starting with high-yield exosome development using Esco Aster’s cell line platform. The technical reports of process, analytical, and formulation development, exosome drug loading, GMP engineering runs, and stability studies supported Shine-On’s IND submission. The IND was cleared by the U.S. FDA in Q1 2025. Furthermore, Esco Aster is providing technical services for exploratory exosome loading feasibility studies per Shine-On’s instruction. Shine-On Biomedical is an emerging innovator in exosome-based drug delivery. ShineOn’s proprietary product, SOB100, a HLA-G targeted exosome drug delivery carrier, has passed the U.S. FDA IND review and ongoing Phase I study, making it as a first-in-class–potential HLA-G targeted exosome platfo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom